PHARMACOKINETICS AND METABOLISM OF ANTIEPILEPTIC DRUGS IN ELDERLY PATIENTS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 我们的目标是研究高龄对抗癫痫药物(AED)药代动力学和代谢的影响。选定的老年和成年男性和女性因任何原因服用苯妥英钠(PHT)或卡马西平(CBZ)作为单一疗法或与其他非干扰性药物(包括其他非干扰性AEDs)一起服用的患者将接受评估。患者将接受其口服剂量的一部分CBZ或PHT，在10分钟内(仅一次)以100毫克的稳定标签配方静脉给药。稳定标记的CBZ和PHT没有放射性，表现出与未标记的CBZ或PHT相同的动力学和代谢。将对血液样本和尿液采集进行分析。 在CBZ项目的子研究CBZ去诱导研究中，受试者在三个月内的四个时间点接受静脉注射制剂，同时停用CBZ方案并切换到另一种抗癫痫药物(AED)。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Our goal is to investigate the effect of advanced age on antiepileptic drug (AED) pharmacokinetics and metabolism. Selected elderly and adult male and female ambulatory patients taking phenytoin (PHT) or carbamazepine (CBZ) for any reason as monotherapy or with other non-interfering medications including other non-interfering AEDs will be evaluated. The patients will receive a portion of their oral dose of CBZ or PHT in a stable-labeled formulation given intravenously as 100 mg over 10 minutes (one time only). Stable-labeled CBZ and PHT are NOT radioactive and exhibit the same kinetics and metabolism as unlabeled CBZ or PHT. Blood samples and urine collections will be analyzed. In the CBZ De-Induction Study, a sub-study of the CBZ Project, subjects receive the intravenous formulation at four time points over three months while being taken off their CBZ regimen and switched to another antiepileptic drug (AED).